Best Quality Tofacitinib CAS NO 477600-75-2 available for sale

Chemical Identity: Tofacitinib (CAS No. 477600-75-2) Description: Tofacitinib is a Janus kinase (JAK) inhibitor, specifically targeting JAK1 and JAK3 isoforms. It modulates immune responses by inhibiting the signaling pathways involved in inflammation and immune cell activation.

Mechanism of Action:

• Tofacitinib exerts its therapeutic effects by inhibiting the activity of Janus kinases (JAKs), which are intracellular enzymes involved in the signaling pathways of various cytokines and growth factors.
• By inhibiting JAK1 and JAK3, tofacitinib interferes with the signaling of multiple pro-inflammatory cytokines, including interleukin (IL)-6, IL-7, IL-15, and interferon gamma (IFN-γ).
• This modulation of cytokine signaling helps to reduce inflammation and suppress immune responses, leading to the alleviation of symptoms in autoimmune diseases.

Indications:

• Tofacitinib is approved for the treatment of several autoimmune diseases, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ulcerative colitis (UC).
• In patients with rheumatoid arthritis, tofacitinib is used as a second-line treatment after inadequate response to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
• In psoriatic arthritis, tofacitinib may be used alone or in combination with methotrexate or other nonbiologic DMARDs.
• Tofacitinib is also indicated for the treatment of moderate to severe active ulcerative colitis in adults who have had an inadequate response, loss of response, or intolerance to conventional therapies.

Dosage Forms:

• Tofacitinib is available in oral tablet form for administration. It is typically supplied in various strengths, such as 5 mg and 10 mg tablets.

Dosage and Administration:

• The dosage of tofacitinib varies depending on the indication and patient's response to treatment.
• In rheumatoid arthritis and psoriatic arthritis, the recommended starting dose is usually 5 mg twice daily, which may be increased to 10 mg twice daily in some patients.
• For ulcerative colitis, the recommended dose is 10 mg twice daily for induction therapy, followed by 5 mg or 10 mg twice daily for maintenance therapy, depending on response.

Adverse Effects:

• Common adverse effects of tofacitinib may include upper respiratory tract infections, headache, diarrhea, nausea, and hypertension.
• Serious adverse effects may include increased risk of serious infections, including tuberculosis, herpes zoster, and opportunistic infections. Other serious risks include malignancies and thromboembolic events.

Monitoring:

• Patients receiving tofacitinib therapy require regular monitoring for signs of infection, including tuberculosis screening before initiation of treatment.
• Monitoring of blood pressure, liver function tests, and lipid levels is also recommended during tofacitinib therapy.

Drug Interactions:

• Tofacitinib may interact with certain medications, including immunosuppressants, live vaccines, and drugs metabolized by cytochrome P450 enzymes.
• Concomitant use of tofacitinib with potent immunosuppressive agents may increase the risk of infection or other adverse effects.

Contraindications:

• Tofacitinib is contraindicated in patients with severe hypersensitivity to tofacitinib or any of its components.
• It should not be used in patients with active severe infections, including active tuberculosis, or in patients with severe hepatic impairment.

Pregnancy and Lactation:

• The safety of tofacitinib during pregnancy and lactation is not well established. It should be used with caution in pregnant or breastfeeding women, and the potential risks and benefits should be carefully considered.